Form 4: Inozyme Pharma Director Sarah M. Bhagat Acquires 28,000 Stock Options

Director Sarah M. Bhagat acquired 28,000 stock options in Inozyme Pharma, Inc. on June 18, 2024, according to a recent SEC filing.

Summary

• Sarah M. Bhagat, a director of Inozyme Pharma, Inc., acquired 28,000 stock options on June 18, 2024.
• The exercise price of these options is $4.40.
• The options vest 100% on June 18, 2025, or immediately prior to the first annual meeting of stockholders occurring after the grant date, if earlier.
• The options expire on June 17, 2034.
• Following the transaction, Ms. Bhagat directly owns 28,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the pharmaceutical industry.
• The vesting schedule of one year is fairly standard.
• Comparing the size of this grant to similar companies like Dicerna Pharmaceuticals (acquired by Novo Nordisk) or Alnylam Pharmaceuticals would provide context on whether this grant is typical for a director role.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company insider.

Key Dates